Non-Dilutive Funding: NIH/NCI Awards OmicXHealth an SBIR Grant

We're excited to share that OmicXHealth has received a Notice of Award for non-dilutive funding from the National Institutes of Health (NIH), through the National Cancer Institute (NCI), as part of the SBIR program.

The award funds our blinded validation study of OmicXScreen for early hepatocellular carcinoma (liver cancer) detection at UT Southwestern alongside business and market assessment work to help de-risk our path to commercialization.

We're deeply grateful for this support, and we hope it marks the beginning of a long and productive relationship with NIH/NCI in the broader mission of early cancer detection at scale.

This is one step in a longer journey. We remain a lean team, so every dollar goes directly toward our core deliverables: validated science that can reach patients soon.

Onward.